ACTION-1 succeeds: Bristol Myers Squibb stock sits 16.11 percent below its high
Published on 10/13/2026 at 11:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- Bristol Myers Squibb reported positive Phase 3 ACTION-1 results for RYZ101 on October 12, 2026.
- Bristol Myers Squibb stock was EUR 51.84 at Lang & Schwarz on October 13, 2026.
- Second-quarter revenue reached USD 12.97 billion, up 5.70 percent year over year.
- Third-quarter 2026 results are scheduled for October 29, 2026.
Bristol Myers Squibb (ISIN US1101221083) was trading at EUR 51.84 at Lang & Schwarz on October 13, 2026 at 11:38 a.m. CEST. The company reported positive Phase 3 ACTION-1 results on October 12, while the stock's latest NYSE quote of USD 57.58 stood 16.11 percent below its 52-week high of USD 68.64.
Three pipeline events shape the story
On September 18, 2026, Bristol Myers Squibb scheduled its third-quarter report for October 29, 2026, with an 8:00 a.m. ET conference call. On October 9, MarketBeat reported that Bank of America cut its target from USD 71.00 to USD 66.00.
On October 12, Bristol Myers Squibb said the planned interim analysis of ACTION-1 met its primary endpoint. The randomized Phase 3 trial tested RYZ101 against investigator choice of standard care in patients with gastroenteropancreatic neuroendocrine tumors whose disease had progressed after lutetium-177 treatment.
What does ACTION-1 add?
The company said progression-free survival improved in a statistically significant and clinically meaningful way, while safety results remained consistent with RYZ101's known profile. Detailed results are expected at a future medical meeting, so the October 12 announcement establishes the direction of the trial but not a detailed efficacy dataset.
Quarterly numbers set the benchmark
In the second quarter of 2026, Bristol Myers Squibb generated USD 12.97 billion in revenue and reported USD 2.04 in earnings per share, according to MarketBeat. Revenue increased 5.70 percent from the same quarter a year earlier, and earnings per share exceeded the USD 1.60 consensus estimate by USD 0.44.
That operating comparison matters because the pipeline announcement is being judged against a business already producing double-digit quarterly revenue. The October 29 report will show whether the commercial portfolio continues to offset development risk and the pressure from future patent expirations.
Stock remains below its yearly high
The latest NYSE quote was USD 57.58 on October 12, 2026 at 4:00 p.m. EDT, against a 52-week range of USD 42.52 to USD 68.64. At Lang & Schwarz, the stock was trading at EUR 51.84 on October 13, 2026 at 11:38 a.m. CEST.
The further course of trading is shown by the continuously updated real-time quote of Bristol Myers Squibb stock.
Bristol Myers Squibb stock facts
- Company: Bristol-Myers Squibb Company
- ISIN: US1101221083
- Ticker: BMY
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 13, 2026, 11:38 a.m. CEST): EUR 51.84
- Market capitalization: USD 117.6 billion (as of October 12, 2026)
- 52-week range: USD 42.52-68.64 (as of October 12, 2026)
- Sector / Industry: Health Care / Pharmaceuticals
- Next earnings date: October 29, 2026
Market context: Market report S&P 500.
